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Abstract. Ventricular arrhythmic and electrophysi-
ological properties were examined during normokalaemia 
(5.2 mM [K+]), hypokalaemia (3 mM [K+]) or hypokalaemia in 
the presence of 0.1 or 2 mM heptanol in Langendorff-perfused 
mouse hearts. Left ventricular epicardial or endocardial 
monophasic action potential recordings were obtained 
during right ventricular pacing. Hypokalaemia induced 
ventricular premature beats (VPBs) in 5 of 7 and ventricular 
tachycardia (VT) in 6 of 7 hearts (P<0.01), prolonged action 
potential durations (APD90) from 36.2±1.7 to 55.7±2.0 msec 
(P<0.01) and shortened ventricular effective refractory 
periods (VERPs) from 44.5±4.0 to 28.9±3.8 msec (P<0.01) 
without altering conduction velocities (CVs) (0.17±0.01 m/sec, 
P>0.05), reducing excitation wavelengths (λ, CV x VERP) 
from 7.9±1.1 to 5.1±0.3 mm (P<0.05) while increasing critical 
intervals (CI, APD90-VERP) from -8.3±4.3 to 26.9±2.0 msec 
(P>0.001). Heptanol (0.1 mM) prevented VT, restored effec-
tive refractory period (ERP) to 45.2±2.9 msec without altering 
CV or APD, returning λ to control values (P>0.05) and CI to 
8.4±3.8 msec (P<0.05). Heptanol (2 mM) prevented VPBs and 
VT, increased ERP to 67.7±7.6 msec (P<0.05), and reduced CV 
to 0.11±0.1 m/sec (P<0.001) without altering APD (P>0.05), 
returning λ and CI to control values (P>0.05). Anti-arrhythmic 
effects of heptanol during hypokalaemia were explicable by 
ERP changes, scaling λ and CI.
Introduction
Cardiac excitation involves an orderly sequence of action 
potential activation and recovery, and subsequently, its 
conduction through successive myocardial regions via 
gap junctions (1-3). Disruption of these processes, through 
alterations in conduction velocity (CV), effective refractory 
period (ERP) or action potential duration (APD), can result in 
ventricular arrhythmias. This can be exemplified by hypoka-
laemia, a commonly encountered condition in clinical practice 
and an acquired cause of long QT syndrome (4). Prolongations 
in the electrocardiographic QT interval reflect increases in 
APDs, in turn predisposing to a particular form of ventricular 
tachycardia known as torsades de pointes (5).
A strategy used to prevent such adverse rhythms is to 
increase the ERP. This can be achieved using drugs that act on 
various cardiac ion channels in the cell membrane. However, 
certain anti-arrhythmic agents can have the undesired and 
paradoxical effects of themselves inducing arrhythmias (6) 
through mechanisms such as APD prolongation (7) or CV 
slowing (8). Therefore, there is a requirement to develop novel 
drugs with improved safety profiles (9). One potential method 
is to target intercellular communication, which is mediated 
by gap junctions. For example, gap junction openers such as 
rotigaptide (10), and inhibitors such as carbenaloxone (11), 
have demonstrated promising results of preventing ventricular 
arrhythmias induced by ischaemia in dogs.
Mouse hearts have been extensively used to model arrhyth-
mogenesis due to their amenability for pharmacological and 
genetic manipulation (12). In particular, the Langendorff perfu-
sion system has the benefit of containing all myocardial cell 
types with intact intercellular coupling (13). Hypokalaemia has 
previously been shown to elicit frequent early after-depolarisa-
tion phenomena and sustained ventricular tachy-arrhythmias, 
with prolonged APDs and reduced ERPs implicated as the 
underlying re‑entrant substrates (14,15). Heptanol is a specific 
gap junction inhibitor when <1 mM (16,17), but also blocks 
sodium channels at ≥2 mM (16,18). Previous experiments 
have demonstrated ventricular tachy-arrhythmias occur-
ring at 2 mM heptanol, which was previously attributed to 
its effect on slowing CV despite simultaneously increasing 
ERP and leaving APD unaltered (19). At 0.1 mM, it had no 
pro-arrhythmic effects, increased ERP without altering CV or 
APD. The present study hypothesised that combining hypo-
kalaemia and heptanol may paradoxically prevent ventricular 
arrhythmogenesis. This may be explained through heptanol 
reversing the ERP changes produced by hypokalaemia. 
However, VPBs and ventricular tachycardia (VT) as well as 
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the electrophysiological parameters observed during hypoka-
laemia may be affected differently at 0.1 and 2 mM heptanol 
due to their differing ion channel specificities.
The present experiments first confirmed previous obser-
vations of VPBs and VT during hypokalaemic conditions. 
Heptanol at 0.1 mM prevented VT whilst returning ERPs to 
normokalaemic values without affecting APDs or CVs. By 
contrast, at 2 mM, it prevented VPBs and VT, associated with 
increased ERPs, despite reduced CVs and no further changes to 
APDs. The present results suggest that the net effect of a phar-
macological agent on arrhythmogenicity is dependent upon 
the association between ERP, CV and APD, and that changes 
in a single parameter are sufficient to influence the arrhythmic 
outcome. It appears that wavelength shortening consistently 
predicted the occurrence of VT, implying that re-entry may be 
an underlying mechanism. Gap junction inhibitors, not just its 
openers, have protective effects against arrhythmias and their 
therapeutic effects warrant further exploration.
Materials and methods
Solutions. The experiments described in the present study used 
Krebs-Henseleit solution (119 mM NaCl, 25 mM NaHCO3, 4 mM 
KCl, 1.2 mM KH2PO4, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM 
glucose and 2 mM sodium pyruvate) (pH 7.4) that had been 
bicarbonate-buffered and bubbled with 95% O2-5% CO2 (20). 
Hypokalaemic solution was prepared by decreasing the amount 
of KCl added to produce a final [K+] of 3 mM.
Preparation of Langendorff‑perfused mouse hearts. In 
total, 14 mice (wild-type, 129 genetic background) between 
5 and 7 months of age were used in the study. These mice 
were maintained in an animal facility at room temperature 
(21±1˚C), subject to a 12:12 h light/dark cycle with free 
access to sterile rodent chow and water. All the experiments 
described here complied with the UK Animals (Scientific 
Procedures) Act 1986. The procedures for the preparation 
of Langendorff-perfused mouse hearts are as follows. Mice 
were sacrificed by cervical dislocation in accordance with 
Sections 1(c) and 2 of Schedule 1 of the UK Animals (Scientific 
Procedures) Act 1986. The hearts were rapidly excised and 
immediately submerged in ice-cold Krebs-Henseleit solution. 
Cannulation of the aorta was achieved using a tailor-made 
21‑gauge cannula that had been prefilled with ice‑cold buffer. 
Using a micro-aneurysm clip (Harvard Apparatus, Kent, 
UK), the heart was securely attached to the perfusion system. 
Retrograde perfusion was initiated at a rate of 2-2.5 ml min-1 
using a peristaltic pump (Watson-Marlow Bredel pumps 
model 505S; Falmouth, Cornwall, UK) with the perfusate 
passing through 200 and 5 µm filters successively and heated 
to 37˚C using a water jacket and circulator before reaching 
the aorta. The hearts that regained their pink colour and 
spontaneous rhythmic activity were studied further (~90%). 
The remaining 10% were discarded. Perfusion took place 
for a further 20 min to minimise any residual effects of 
catecholamine released endogenously, prior to studying the 
electrophysiology of the perfused hearts.
Stimulation protocols. Electrical stimulation was achieved 
using paired platinum electrodes (1 mm interpole distance) 
placed at the basal right ventricular epicardium. This occurred 
at 8 Hz, using square wave pulses that were 2 msec in duration, 
with a stimulation voltage set to thrice the diastolic threshold 
(Grass S48 stimulator; Grass-Telefactor, Slough, UK) immedi-
ately following the start of perfusion. Programmed electrical 
stimulation (PES) using the S1S2 protocol was used to assess 
arrhythmogenicity and identify re-entrant substrates. This 
consisted of a drive train of eight regularly paced S1 stimuli 
separated by a 125 msec basic cycle length (BCL), followed 
by premature S2 extra-stimuli every ninth stimulus. S1S2 
intervals first equalled the pacing interval and following this 
were successively reduced by 1 msec with each nine stimulus 
cycle until arrhythmic activity was initiated or refractoriness 
was reached, whereupon the S2 stimulus elicited no response.
Recording procedures. Recordings of the monophasic action 
potentials (MAPs) from the left ventricular epicardium were 
obtained using a MAP electrode (Linton Instruments, Harvard 
Apparatus). MAPs from the left ventricular endocardium 
were obtained using a custom-made MAP electrode that was 
made from two strands of 0.25 mm Teflon‑coated silver wire 
(99.99% purity; Advent Research Materials, Oxfordshire, 
UK). The tips of the electrode were galvanically-chlorided 
to eliminate DC offset. The endocardial electrode was 
introduced through a small access window made in the 
inter-ventricular septum and subsequently positioned on 
the lateral wall of the left ventricular cavity. The positions 
for stimulating and recording electrodes were maintained at 
constant positions, with a constant inter-electrode distance of 
3 mm. This allowed conduction velocities to be determined 
from the activation latencies. All recordings were performed 
using a BCL of 125 msec (8 Hz) to exclude rate-dependent 
differences in APDs. MAPs were pre-amplified using a 
NL100AK head stage, amplified with a NL104A amplifier 
and band pass filtered between 0.5 Hz and 1 kHz using a 
NL125/6 filter (Neurolog, Hertfordshire, UK) and subse-
quently digitized (1401plus MKII; Cambridge Electronic 
Design, Cambridge, UK) at 5 kHz. The samples were anal-
ysed using Spike2 software (Cambridge Electronic Design). 
MAP waveforms that did not match the previous established 
stringent criteria for MAP signals (21) were rejected. They 
must have stable baselines, fast upstrokes, with no inflections 
or negative spikes, and a rapid first phase of repolarization. 
Repolarization of 0% was measured at the peak of the MAP 
and 100% repolarization was measured at the point of return 
of the potential to baseline (21-23).
The following parameters were obtained from the 
experimental records: i) Activation latency, defined as the time 
difference between the stimulus and the peak of the MAP; 
and ii) CV, as the ratio of the inter-electrode distance to the 
activation latency. As the latter distance was kept constant, 
CVs were inversely proportional to the corresponding activa-
tion latencies; iii) ERP, defined as the longest S1S2 interval 
at which the S2 extrastimulus failed to initiate a ventricular 
signal during PES; iv) APDx, the time difference between the 
peak of the MAP and x=30, 50, 70 and 90% repolarisation; 
v) ΔAPDx, given by the endocardial - epicardial difference; 
vi) local critical intervals for re-excitation at the epicardium 
or endocardium, given by APD90 - ERP; vii) transmural 
critical interval for re-excitation of the endocardium by the 
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epicardium given by (epicardial activation latency + epicar-
dial APD90) - [endocardial activation latency + endocardial 
ventricular effective refractory periods (VERP)], and of the 
epicardium by the endocardium given by (endocardial acti-
vation latency + endocardial APD90) - (epicardial activation 
latency + epicardial VERP) (15); viii) excitation wavelength 
given by CV x ERP; ix) APD90 restitution gradient obtained 
from restitution curves plotting APD90 against the previous 
diastolic interval (DI), assuming its maximum value at the 
shortest S1S2 interval studied; x) critical DI, DIcrit, defined as 
the DI at which the gradient of the APD90 restitution curve 
reaches unity; xi) maximum APD90 reduction, a measure of 
APD90 restitution heterogeneity, defined as the maximum 
APD90 reduction observed between the longest and shortest 
S1S2 intervals achieved during PES; xii) CV restitution 
gradient obtained from restitution curves plotting CV against 
the previous DI, assuming its maximal value at the shortest 
S1S2 interval studied; xiii) CV restitution curve time constant, 
τ; xiv) maximum CV reduction, a measure of CV restitution 
heterogeneity, defined as the maximum CV reduction observed 
between the longest and shortest S1S2 interval achieved during 
PES (24).
Statistical analysis. All the values are expressed as 
mean ± standard error of the mean. Different experimental 
groups were compared by one-way analysis of variance 
(ANOVA) and Student's t-test as appropriate. P<0.05 was 
considered to indicate a statistically significant difference. 
Categorical data were compared with Fisher's exact test 
(one-tailed), with P<0.05 considered to indicate a statistically 
significant difference. 
Results
Ventricular arrhythmogenicity, action potential activation 
and recovery properties. Ventricular arrhythmogenicity and 
its association with action potential activation and recovery 
properties were examined under normokalaemic condi-
tions (5.2 mM [K+]o), hypokalaemia alone (3 mM [K+]o) and 
hypokalaemia in the presence of 0.1 or 2 mM heptanol in 
Langendorff-perfused mouse hearts. The right ventricular 
epicardium was electrically stimulated using either regular 
8 Hz pacing or PES (25,26). MAP recordings were obtained 
from the left ventricular epicardium or endocardium. The 
epicardial stimulating and recording electrodes were sepa-
rated by a constant distance of 3 mm, which permitted CVs 
to be calculated from the respective activation latencies and 
therefore enabled their comparisons between experiments. A 
VPB was defined as an action potential occurring prior to full 
repolarisation, and VT was defined as a succession of five or 
more action potentials at intervals closer than the BCL.
Concentrations of 0.1 and 2 mM heptanol exert anti‑arrhythmic 
effects under hypokalaemic conditions. The initial experiments 
conducted during regular pacing demonstrated consistent 
ventricular activity in the absence of spontaneous arrhyth-
mias in all of the seven hearts studied under normokalaemic 
conditions (Fig. 1A). By contrast, VPBs (Fig. 1B) occurred 
in 5 hearts (Fisher's exact test, P<0.05) and VT (Fig. 1C) in 
6 hearts (P<0.01) during hypokalaemia, as summarised in 
Fig. 1F and G, respectively. To test the effects of heptanol, it 
was first applied at 0.1 mM under hypokalaemic conditions 
and was found to prevent VT in 6 hearts (P<0.01) without 
Figure 1. Representative traces of epicardial monophasic action potential (MAP) recordings obtained during regular 8 Hz pacing. (A) A typical regular 
rhythm with each MAP occurring directly after its preceding stimulus can be observed under control conditions (5.2 mM [K+]). (B) Hypokalaemia (3 mM 
[K+]) produced both ventricular premature beats (VPBs) and (C) ventricular tachycardia (VT). (D) Heptanol at 0.1 mM prevented VT but did not affect VPBs, 
(E) whereas at 2 mM prevented VPBs and VT during hypokalaemic conditions. (F) The proportion of hearts showing VPBs was significantly increased by 
hypokalaemia (Fisher's exact test, *P<0.05). This was unaltered by heptanol at 0.1 mM (P>0.05), but subsequently decreased at 2 mM (†P<0.05). (G) The 
proportion of hearts showing VT was significantly increased by hypokalaemia (**P<0.01) and subsequently decreased by 0.1 and 2 mM heptanol (††P<0.01).
  A   B   C
  G  F
  E  D
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altering the incidence of VPBs (P>0.05) (Fig. 1D). Raising its 
concentration to 2 mM prevented both VPBs in 5 hearts and 
VT in 6 hearts, respectively (P<0.05) (Fig. 1E).
The second set of experiments explored for re-entrant 
substrates using PES, imposing extrasystolic S2 stimuli 
following trains of regular S1 pacing stimuli. The S1S2 
interval was initially at the BCL and subsequently reduced by 
1 msec with each cycle until the S2 stimuli produced either 
arrhythmic activity or refractoriness, with the latter indicating 
that the VERP had been reached. None of the hearts studied 
demonstrated evidence of arrhythmias under normokalaemic 
conditions (Fig. 2A; incidence summarised in Fig. 2E). By 
contrast, VT was induced by PES in 6/7 hearts during hypo-
kalaemia (Fig. 2B) (P<0.01). Introduction of 0.1 (Fig. 2C) and 
2 mM (Fig. 2D) heptanol prevented VT from occurring in 
5 (P<0.05) and 6 out of these 7 hearts (P<0.01), respectively.
Anti‑arrhythmic effects of heptanol can be explained by 
VERP changes despite abnormal CVs and APDs. Previous 
studies using animal models of hypokalaemia have associ-
ated its pro-arrhythmic effects with reduced CVs (27), 
prolonged epicardial APDs, and prolonged or unaltered 
endocardial APDs, leading to decreased ΔAPDs given by 
the epicardial-endocardial difference (14) and decreased 
VERPs (15). By contrast, pro-arrhythmic effects of heptanol 
have been attributed to reduced CVs despite increased VERPs 
and normal APDs (19). To quantify the effect of heptanol on 
hypokalaemia-induced arrhythmogenesis, these parameters 
were determined from the data obtained in the aforementioned 
experiments (n=7) and correlated with the arrhythmogenicity 
findings.
Firstly, epicardial activation latency was 17.4±0.8 msec 
(Fig. 3A) under normokalaemic conditions, corresponding to a 
CV of 0.17±0.01 m/sec (Fig. 3B), while endocardial activation 
latency was 17.4±1.4 msec (Fig. 3C). These values were not 
altered by hypokalaemia alone or 0.1 mM heptanol (ANOVA, 
P>0.05). By contrast, 2 mM heptanol increased epicardial and 
endocardial activation latencies to 29.0±2.3 msec (P<0.001) 
and 23.2±2.0 msec (P<0.05), respectively, and therefore 
decreased CVs to 0.11±0.01 m/sec (P<0.001). Epicardial 
activation latencies were not significantly different from 
their corresponding endocardial activation latencies under 
any of the aforementioned pharmacological conditions 
studied (P>0.05).
Secondly, epicardial APD90 was increased from 36.2±1.7 to 
55.7±2.0 msec by hypokalaemia (P<0.001) (Fig. 4A), as were 
APD70 (P<0.01) (Fig. 4B) and APD50 (P<0.05) (Fig. 4C) but 
not APD30 (P>0.05) (Fig. 4D). By contrast, endocardial 
APD90 (Fig. 4E), APD70 (Fig. 4F), APD50 (Fig. 4G) and 
APD30 (Fig. 4H) (P>0.05) were unaltered. These findings 
corresponded to decreased ΔAPD90 (P<0.01) (Fig. 5A) and 
ΔAPD70 (P<0.05) (Fig. 5B), but unaltered ΔAPD50 and ΔAPD30 
(P>0.05) (Fig. 5C and D, respectively). Neither 0.1 nor 2 mM 
heptanol further altered any of the APDx and therefore ΔAPDx 
(P>0.05 in all cases).
Finally, epicardial (Fig. 6A) and endocardial (Fig. 6B) 
VERPs were decreased from 44.5±4.0 to 28.9±3.8 msec 
(P<0.01) and from 38.2±1.6 to 22.0±2.3 msec (P<0.001), 
Figure 2. Representative monophasic action potential (MAP) recordings obtained during programmed electrical stimulation. (A) There was no evidence of 
provoked arrhythmias under control conditions. By contrast, (B) ventricular tachycardia (VT) was observed in under hypokalaemic conditions and inhibited 
by (C) 0.1 and (D) 2 mM heptanol. (E) The proportion of hearts showing provoked VT was significantly increased by hypokalaemia from 0/7 to 6/7 hearts 
(Fisher's exact test, **P<0.01). This was reduced to 1/7 and 0/7 hearts following further introduction of 0.1 (†P<0.05) and 2 mM (††P<0.01) heptanol, respectively.
  A   B
  C   D
  E
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respectively, during hypokalaemia. However, these were 
restored to 45.2±2.9 and 38.5±4.6 msec, respectively (P<0.001 
and P<0.01), by 0.1 mM heptanol, which were indistinguish-
able from values obtained under normokalaemic conditions. 
By contrast, they were increased to 67.7±7.6 (P<0.05) and 
56.6±7.4 msec (P<0.05), respectively, at a higher concentration 
of 2 mM. Epicardial VERPs were significantly greater than the 
corresponding endocardial VERPs in the presence of 2 mM 
heptanol (P<0.05), but not under any other pharmacological 
conditions (P>0.05).
Figure 3. (A) Epicardial activation latency and (B) conduction velocity (CV), and (C) endocardial activation latency obtained during regular 8 Hz pacing. 
These were not altered by hypokalaemia whether prior or subsequent to introduction of 0.1 mM heptanol (analysis of variance, P>0.05). By contrast, epicardial 
(***P<0.001) and endocardial (*P<0.05) activation latencies were significantly increased by 2 mM heptanol, corresponding to reduced CVs (***P<0.001). The 
epicardial activation latencies were not significantly different from the corresponding endocardial activation latencies under all pharmacological conditions 
studied (P>0.05).
  A   B   C
Figure 4. Epicardial action potential durations (APDx) at (A) x=90, (B) 70, (C) 50 and (D) 30% repolarisation obtained during regular 8 Hz pacing. Hypokalaemia 
increased epicardial APD90 (ANOVA, ***P<0.001), APD70 (**P<0.01) and APD50 (*P<0.05) values but left APD30 unaltered (P>0.05). 0.1 and 2 mM heptanol 
did not further alter these values (P>0.05). Endocardial APDx at (E) x=90, (F) 70, (G) 50 and (H) 30% repolarisation obtained during regular 8 Hz pacing. 
Hypokalaemia treatment whether prior or subsequent to introduction of 0.1 mM and 2 mM heptanol did not further alter epicardial APD90, APD70, APD50 and 
APD30 (ANOVA, P>0.05). ANOVA, analysis of variance.
  A   B
  C   D
  E   F
  G   H
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Anti‑arrhythmic effects of heptanol correlate directly with 
critical intervals and excitation wavelengths. Increases in 
critical intervals (APD90 - VERP) either locally or across 
the myocardial wall (15) and decreases in excitation wave-
lengths (CV x VERP) (19,28) have been associated with 
increased arrhythmic tendency. The local critical intervals 
for the epicardium and endocardium are given by epicardial 
APD90 - epicardial VERP and endocardial APD90 - endocar-
dial VERP, respectively. The critical interval for transmural 
re-excitation of the epicardium by the endocardium is given 
by (endocardial latency + endocardial APD90) - (epicardial 
latency + epicardial VERP), and that of the endocardium by 
the epicardium is given by (epicardial latency + epicardial 
APD90) - (endocardial latency + endocardial VERP).
The local critical intervals obtained from the epicar-
dium (Fig. 7A) were found to increase from -8.3±4.3 to 
26.9±2.0 msec by hypokalaemia (P<0.001). These were 
subsequently reduced by 0.1 mM (P<0.05) and restored to 
normokalaemic values by 2 mM heptanol (P>0.05). Similar 
patterns of changes were observed for local critical intervals 
obtained from the endocardium (Fig. 7B), and for transmural 
critical intervals reflecting the period permitting re‑excitation 
of the endocardium by the epicardium (Fig. 7C) and of the 
epicardium by the endocardium (Fig. 7D). Excitation wave-
lengths (Fig. 7E) were significantly reduced from 7.9±1.1 to 
5.1±0.3 mm by hypokalaemia (P<0.05), and returned to 
normokalaemic values by 0.1 and 2 mM heptanol (P>0.05).
Heptanol does not alter APD or CV restitution properties 
during hypokalaemia. Previous studies have associated 
increased arrhythmogenicity with increases in maximum 
APD90 restitution gradients, critical diastolic intervals (DIs 
and DIcrit), and maximum APD90 reduction between the 
longest and shortest S1S2 intervals studied under hypoka-
laemic conditions (29). In other models systems, by contrast, 
increased arrhythmogenicity was attributed to abnormal CV 
Figure 6. (A) Epicardial and (B) endocardial ventricular effective refractory periods (VERPs) obtained during programmed electrical stimulation. Significant 
differences from *normokalaemic and †hypokalaemic values, respectively. Epicardial and endocardial VERPs were significantly reduced by hypokalaemia 
(analysis of variance, **P<0.01 and ***P<0.001 for epicardium and endocardium, respectively), but restored to normokalaemic values by 0.1 mM heptanol 
(P>0.05). These were further increased by 2 mM heptanol (*P<0.05). (††P<0.01, †††P<0.001).
  A   B
Figure 5. ΔAPDx given by endocardial APDx - epicardial APDx at (A) x=90, (B) 70, (C) 50 and (D) 30% repolarisation obtained during regular 8 Hz pacing. 
Hypokalaemia decreased ΔAPD90 (Student's t-test), ΔAPD70, but ΔAPD50 and ΔAPD30 were unaltered. These values were not further altered by 0.1 or 2 mM 
heptanol (P>0.05). APD, action potential duration. (*P<0.05, **P<0.01, ***P<0.001).
  A   B
  C   D
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restitution. Thus, increased maximum CV restitution gradients 
were observed in untreated rabbit hearts (30); increased time 
constants of the fitted restitution curves (i.e., decreased CV 
restitution gradients) was demonstrated in ion channel models 
and diacetyl monoxime-treated rabbit hearts (31,32); increase 
in maximal CV reductions between the longest and shortest 
S1S2 intervals studied was seen in D600-treated rabbit 
hearts (24).
In the present study, restitution curves were constructed 
using the PES data obtained above, by plotting APD90 or CV 
against the preceding DI, and were then fitted with an expo-
nential function of the form y=y0+Ae-x/τ by a least-squares 
method using a Levenberg-Marquardt algorithm. y represents 
either APD90 or CV, and x represents DI, whereas y0, A and τ 
are constants. The gradient is given by
 
assuming its maximal value at the shortest S1S2 interval 
reached during PES. DIcrit was defined as the DI at which the 
gradient of the fitted function reached unity. Maximum APD90 
or CV reduction, reflecting heterogeneity in restitution, was 
defined as the difference between values obtained at the longest 
S1S2 interval and those obtained at the shortest S1S2 interval.
Fig. 8 shows examples of APD90 restitution curves 
(solid lines, left ordinates) and their gradients (broken lines, 
right axes) obtained at the epicardium (Fig. 8A-D) and the 
endocardium (Fig. 8E-H) under normokalaemic and hypo-
kalaemic conditions prior and subsequent to the introduction 
of 0.1 or 2 mM heptanol; fitted parameters summarised in 
Tables I and II, respectively. APD90 decreased with decreasing 
DIs under all pharmacological conditions studied.
The maximal APD90 restitution gradients (Fig. 9A), 
DIcrit (Fig. 9B) and maximum APD90 reductions (Fig. 9C) in the 
epicardium were increased by hypokalaemia (P<0.05, P<0.01 
and P<0.05, respectively). Introduction of 0.1 or 2 mM heptanol 
restored maximum APD90 reductions to normokalaemic values 
(P>0.05), but did not further alter maximum APD90 restitution 
gradients or DIcrit. All these corresponding parameters in the 
endocardium remained unaltered (Fig. 9D-F) during hypoka-
laemia conditions whether prior or subsequent to introduction 
of 0.1 or 2 mM heptanol (P>0.05 in all cases).
Fig. 10 progresses to show examples of epicardial CV resti-
tution curves (solid lines, left ordinates) and their gradients 
(broken lines, right axes) obtained under normokalaemic and 
hypokalaemic conditions prior and subsequent to introduction 
of 0.1 and 2 mM heptanol (Fig. 10A‑D), with fitted parameters 
summarised in Table III. However, there was no difference in 
maximum CV restitution gradients (Fig. 10E), time constants 
τ of the restitution curves (Fig. 10F) or maximum CV 
reductions (Fig. 10G) between these pharmacological condi-
tions (P>0.05).
Taken together, all the above findings demonstrate 
that hypokalaemia elicited VPBs and VT, associated with 
prolonged epicardial APD90, unaltered endocardial APD90, and 
reduced epicardial and endocardial VERPs despite unaltered 
activation latencies and CVs. These changes corresponded to 
decreased ΔAPDs, increased critical intervals and reduced 
excitation wavelengths. Dynamic substrates in the form of 
abnormal APD restitution also appeared to have a role in its 
arrhythmogenesis, as exemplified by increases in maximum 
APD90 restitution gradients, DIcrit and maximum APD90 
reductions observed during PES. However, CV restitution did 
not have an apparent contribution, as maximum CV restitu-
tion gradients, time constants of CV restitution curves and 
maximum CV reductions all remained unchanged. Heptanol 
at 0.1 mM prevented VT by normalising VERPs, resulting in 
normal critical intervals and normal excitation wavelengths. 
Table I. Parameters for epicardial APD90 restitution curves obtained during programmed electrical stimulation.
Condition y0, msec A, msec τ, msec
Control 45.2±2.9 -23.2±3.6 21.7±4.4
Hypo K+ 51.1±2.0 -108.3±62.6 12.6±4.5
Hypo K+ + 0.1 mM heptanol 55.5±2.2 -82.1±40.0 4.7±1.0
Hypo K+ + 2 mM heptanol 60.0±5.7 -180.1±118.0 11.2±4.8
APD, action potential duration.
Table II. Parameters for endocardial APD90 restitution curves obtained during programmed electrical stimulation.
Condition y0, msec A, msec τ, msec
Control 43.6±3.6 -124.6±97.8 39.0±13.6
Hypo K+ 54.3±19.8 -36.6±18.9 20.4±26.5
Hypo K+ + 0.1 mM heptanol 52.0±9.8 -48.5±25.0 50.9±42.4
Hypo K+ + 2 mM heptanol 62.5±22.3 -31.0±20.1 15.4±34.9
APD, action potential duration.
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At 2 mM, it prevented VPBs and VT by increasing VERPs 
despite reducing CVs, which corresponded to reduced 
critical intervals and increased excitation wavelengths. These 
anti-arrhythmic effects observed at heptanol concentrations 
were associated with restoration of maximum APD90 reduc-
tions to normokalaemic values despite no further changes to 
APDs or the remaining APD90 and CV restitution parameters.
Discussion
Ventricular arrhythmias represent a significant cause of sudden 
cardiac death, accounting for around 60,000 fatalities in the 
UK (33), 200,000 fatalities in the US (34) and 4-5 million 
fatalities worldwide (35) per year. Hypokalaemia is a cause of 
electrocardiographic QT prolongation, reflecting delayed action 
potential repolarisation (4), which predisposes to a particular 
form of polymorphic VT termed torsade de pointes (5). It is the 
most common electrolyte abnormality identified in hospital-
ised patients (36) and therefore represents an important cause 
of arrhythmias observed in clinical practice (37).
Ventricular arrhythmic properties of hypokalaemic 
Langendorff-perfused mouse hearts were examined in the 
presence and absence of 0.1 or 2 mM heptanol. This is an agent 
that reversibly inhibits gap junctions at concentrations <1 mM 
and also sodium channels ≥2 mM (16,18). Previous studies have 
described pro-arrhythmic effects of hypokalaemia (14,15,29) 
or heptanol (19). Heptanol (2 mM) is known to induce 
ventricular tachy-arrhythmias through decreases in CVs, 
despite also increasing VERPs and leaving APDs unchanged 
under normokalaemic conditions. The central hypothesis 
here is that changes in VERPs produced by heptanol could 
compensate for prolonged APDs and thereby abolish arrhyth-
mogenesis produced by hypokalaemia. This may be explicable 
by changes in critical intervals given by APD - VERP and 
excitation wavelengths given by CV x VERP.
Monophasic action potential (MAP) recordings were 
obtained from the left ventricular epicardium or endocar-
dium. Previous studies have shown that APDs derived from 
such recordings reflect the time courses of the cellular action 
potential obtained from single cells (21,38,39). Two different 
stimulation protocols were used. Firstly, regular pacing at 
8 Hz, close to the in vivo heart rate (40), was used to detect 
spontaneous arrhythmogenesis. This revealed VPBs and VT 
during hypokalaemia in an absence of alterations in CV, in 
Figure 7. (A-D) Critical intervals [action potential durations (APD)90 - ventricular effective refractory periods (VERP)] and (E) excitation wavelength [conduc-
tion velocity (CV) x ventricular effective refractory periods (VERP)]. Significant differences from *normokalaemic and †hypokalaemic values, respectively. 
Local critical intervals obtained from the (A) epicardium were significantly increased by hypokalaemia (Student's t‑test, ***P<0.001) and subsequently reduced 
by 0.1 mM (††P<0.01; †P<0.05) and 2 mM heptanol (†††P<0.001). Those obtained from the (B) endocardium, and transmural critical intervals for re-excitation 
of the endocardium by the (C) epicardium and that of the epicardium by the (D) endocardium exhibited similar patterns of changes. (E) Excitation wavelength 
was significantly reduced by hypokalaemia (analysis of variance, *P<0.05) but returned to normokalaemic values following introduction of 0.1 or 2 mM 
heptanol (P>0.05).
  A   B   C
  D   E
Table III. Parameters for conduction velocity restitution curves obtained during programmed electrical stimulation.
Condition y0, m/sec A, m/sec τ, msec
Control 0.20±0.01 -0.62±0.420 16.7±4.9
Hypo K+ 0.20±0.01 -0.15±0.012 17.1±3.0
Hypo K+ + 0.1 mM heptanol 0.16±0.01 -0.15±0.027 13.5±1.6
Hypo K+ + 2 mM heptanol 0.16±0.06 -0.18±0.082 15.1±5.2
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agreement with previous findings (14). Heptanol (0.1 mM) 
prevented VT without affecting VPBs, but at 2 mM prevented 
both despite a reduction in CV.
Secondly, PES procedures, which delivered increasing 
premature S2 stimuli following trains of regularly-timed S1 
stimuli, were used to detect the presence of re-entrant substrates, 
as has been performed in clinical practice (25). This protocol 
also allowed exploration of the role of CV and APD restitution 
in hypokalaemia-induced arrhythmogenicity (29,30,41). During 
hypokalaemia, an increase in the proportion of hearts showing 
provoked VT was observed. This was associated with prolonged 
epicardial, but unaltered endocardial APDs and reduced epicar-
dial and endocardial VERPs, in an absence of alterations in 
CVs. Epicardial APD restitution gradients and critical diastolic 
intervals were increased. The difference between epicardial 
APD obtained from the longest S1S2 interval and APD obtained 
from the shortest S1S2 interval studied was increased, reflecting 
an increased heterogeneity in APD restitution (24). The latter 
finding could be explained by reduced VERPs, which would 
allow shorter S1S2 intervals and therefore shorter APDs to 
be attained. Endocardial APD restitution gradients, critical 
diastolic intervals and APD differences were all unaltered. CV 
restitution gradients, restitution time constants and restitution 
heterogeneity were not affected. Notably, these results obtained 
during extrasystolic stimulation are in agreement with previous 
findings that were determined by a dynamic pacing protocol (29). 
This confirms the value of using PES in restitution analysis, as 
previously discussed (42). Such a protocol has the advantage 
of safety over dynamic pacing in a clinical setting, which can 
induce myocardial ischaemia from tachycardia pacing (42).
Figure 8. Restitution curves plotting action potential durations (APD)90 against preceding diastolic interval (DI) obtained from the (A-D) epicardium and 
(E‑H) endocardium under control and hypokalaemic conditions prior and subsequent to the introduction of 0.1 or 2 mM heptanol. Curves were fitted with 
mono‑exponential growth functions obtained by least‑squares fitting to the values of APD90 and DI (solid lines, left ordinates). Gradients were obtained by 
differentiation of the fitted functions (broken lines, right axes).
  A   B
  C   D
  E   F
  G   H
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Together, these changes resulted in a negative ∆APD90 
given by endocardial APD90 - epicardial APD90, suggesting a 
reversal of transmural repolarisation gradients, which has previ-
ously been associated with VT (14). The excitation wavelength 
given by CV x VERP was decreased, thereby predisposing the 
hearts to circus-type re-entry (43). Furthermore, there was an 
increase in the critical interval given by APD - VERP, which 
would increase the likelihood of re-excitation occurring prior 
to full action potential repolarisation (15). This may reflect an 
underlying re-entrant mechanism previously termed prolonged 
repolarisation-dependent re-excitation (44) and phase 2 
re-entry (45) described in Brugada syndrome.
Heptanol (0.1 mM) prevented the induction of VT and 
reversed ERP changes, despite leaving APD abnormalities and 
CV unaffected. This in turn led to the return of the excitation 
wavelength and critical interval to normokalaemic values, 
Figure 10. Restitution curves plotting conduction velocity (CV) against preceding diastolic interval (DI) obtained under (A) control and hypokalaemic condi-
tions (B) prior and subsequent to the introduction of (C) 0.1 or (D) 2 mM heptanol. Curves were fitted with mono‑exponential growth functions obtained by 
least‑squares fitting to the values of CV and DI (solid lines, left ordinates). Gradients were obtained by differentiation of the fitted functions (broken lines, right 
axes). (E) Maximum CV restitution gradients, (F) time constants of restitution curves and (G) maximum CV reductions. None of these parameters was altered 
by hypokalaemia whether prior or subsequent to the introduction of 0.1 or 2 mM heptanol (P>0.05).
  A   B   C   D
  E   F   G
Figure 9. Maximum action potential durations (APD)90 restitution gradients, critical diastolic intervals and maximum APD90 reductions obtained from the 
(A-C) epicardium and (D-F) endocardium. All three parameters were increased by hypokalaemia (*P<0.05, **P<0.01 and *P<0.05, respectively). Of these, 
maximum APD90 reductions were restored to normokalaemic values (P>0.05), whereas maximum APD90 restitution gradients and critical diastolic intervals 
were not further altered by 0.1 or 2 mM heptanol. All three parameters obtained from the endocardium were unaltered by hypokalaemia whether prior and 
subsequent to the introduction of 0.1 or 2 mM heptanol (P>0.05 in all cases). (†P<0.05).
  A   B   C
  D   E   F
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consistent with its effects in preventing VT. The fact that VPBs 
persisted can be explained by prolonged APDs despite normal 
VERPs. This would still permit the re-activation of L-type 
calcium currents, previously implicated in the development of 
early after-depolarisations and subsequently induced triggered 
activity (46-48). Heptanol (2 mM) also prevented VT, which 
is associated with increased ERPs. This is despite persistently 
prolonged APDs and an additional slowing in CV, expected 
to increase arrhythmogenicity. These changes corresponded 
to increased excitation wavelengths and decreased critical 
intervals, both of which would decrease arrhythmogenicity. At 
this concentration, heptanol also prevented VPBs, which can 
be explained by increased VERPs; this would prevent EADs 
from eliciting premature action potentials in the myocardium 
that has not recovered from refractoriness. In the presence 
of either 0.1 or 2 mM heptanol, APD restitution properties 
remained abnormal and CV restitution was not affected during 
hypokalaemia.
The above findings obtained during PES contrast with 
previous observations during normokalaemia in which no 
pro-arrhythmic effects were observed at 0.1 mM, but inducible 
VT was detected at 2 mM heptanol (19). These differences 
can be explained by 2 mM heptanol reducing CV more than it 
increases ERP with a consequent decrease in excitation wave-
length. The anti-arrhythmic action of heptanol in hypokalaemia 
observed here therefore complements previous demonstrations 
of its other beneficial effects in reducing infarct size in mouse 
and rat hearts (49,50) and preventing ventricular arrhythmias 
induced by ischaemia in rat hearts (50,51). A limitation of the 
present study is that the mechanisms of VPBs and VT cannot 
be determined. However, hypokalaemia is known to elicit 
EADs and the VPBs observed may reflect underlying trig-
gered activity. VT could be due to re-entry, although it could 
theoretically be a run of VPBs from focal activity. If VT is 
caused by re-entry, the mechanism is uncertain, whether it is 
due to circus-type, phase 2 or spiral wave re-entry. However, 
premature activation by phase 2 re-entry (or indeed a VPB 
from triggered activity) can in turn facilitate the induction of 
circus-type movement (52).
Protective effects of gap junction in reducing infarct size as 
well as preventing arrhythmogenesis produced by ischaemia 
have previously been described (49,50). Theoretical work has 
shown that in non-uniform tissue, mild loss of gap junction 
function paradoxically increases CV, thereby improving the 
safety margin of conduction (53). Thus, this may remove 
unidirectional blocks, converting them into bilateral conduc-
tion, which would protect against arrhythmogenesis (54-56). 
In the present study, the experiments show that in addition to 
the effects on conduction, the gap junction uncoupler heptanol 
also influences VERP and this may underlie its anti‑arrhythmic 
action in hypokalaemia. This occurred despite a lack of 
correction of the repolarisation abnormalities (prolonged APD 
and increased APD restitution steepness), even in the presence 
of reduced CV, which alone is pro-arrhythmic (19).
The proof of concept demonstrated here is that although 
the arrhythmic risk of hypokalaemia has traditionally been 
associated with prolonged QT interval (57) and increased QT 
dispersion (58), increasing VERPs can prevent arrhythmias 
even when such repolarisation abnormalities persist. Heptanol 
(2 mM) is known to induce VT under normokalaemic 
conditions, at a lower concentration of 0.1 mM, however, it had 
no pro-arrhythmic effects (19). Its possible therapeutic effects 
therefore warrant further investigation.
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